Press Archive - Arriello

Pharmacovigilance under scrutiny.

Despite pharmacovigilance legislation being in place for nearly a decade, many companies are still struggling to fulfill obligations. Arriello's Vanessa Fachada Oliveira writes for Pharmaceutical Technology

Streamlining Pharmacovigilance.

Streamlining Pharmacovigilance: Why the Inertia? via Pharmaceutical Executive and Arriello's Director of Drug Safety Peter Kohut analyse the findings of a survey on how life sciences companies are capitalizing on opportunities to transform workload and data quality management using the latest smart technology.

Why aren’t more companies automating PV data capture?

Why are Safety & Pharmacovigilance departments lagging in their application of smart technology, when the pressures on pharmaceutical organisations to capture, sift and process real-world adverse event data are vast, asks John Price, a life sciences regulatory and safety consultant and advisor to Arriello.

Raising the bar in pharmacovigilance and regulatory outsourcing.

It’s all too easy to underestimate the importance of tight project management when the work being outsourced is something other than clinical trials. Yet, whether the processes involved concern international pharmacovigilance or regulatory information filing, Anna Lukyanova, COO of Arriello, warns life sciences firms not to leave outcomes to chance.

Maintaining Control: The importance of project management.

In process outsourcing, it's easy to neglect the role of formal project management to keep delivery on track; unless it's clinical research, biotech or pharma organisations commonly neglect this when transferring a service externally.

Running a tight ship: The importance of project management.

The importance of not leaving outsourcing outcomes to chance... When biotech and pharma organizations outsource activities it's too easy to neglect the importance of tight project management and stakeholder coordination, explains Arriello's COO Anna Lukyanova.